Blog Section

Ansun BioPharma Named Buzz of BIO Winner for the 2016 BIO International Convention

San Diego – May 9, 2016 – Ansun BioPharma

On Thursday, the Biotechnology Innovation Organization (famously known as BIO), announced the Buzz of BIO winners for the 2016 BIO Convention to be held in San Francisco, California June 6-9, 2016.  Ansun Biopharma won the award in the category of Pipelines of Promise, and EpiBiome won the award in the category of Technologies of Tomorrow.  Ansun will be making a presentation at the convention where it will provide an update on the status of its phase 2 program to treat parainfluenza in immunocompromised patients as well as its pipeline of projects in influenza, RSV and other respiratory viruses.  “We are honored to be part of an organization like BIO that strives to bring innovative therapies like Ansun’s experimental biologics, Paradase™ and Fludase™, to the public to treat dangerous viral infections and other diseases that have so far been untreatable,” stated Dr. Ron Moss, CEO of Ansun.  “We are thrilled to receive the Pipelines of Promise award this year, and we look forward to participating and collaborating with the innovative companies and people who come to BIO each year,” added Mark Attebury, Ansun’s Vice President of Finance.

http://convention.bio.org/BuzzOfBIO/winners.aspx?utm_source=Highroads&utm_medium=email&utm_campaign=Buzz-of-BIO-Winners&utm_content=All&utm_term=Campaign-image

About Ansun BioPharma

Ansun BioPharma is a San Diego based clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral biologic therapies for respiratory viruses.  Ansun BioPharma has two products in late stage clinical development. FluDaseTM is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. ParaDaseTM is an investigational drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of severe parainfluenza infection in immunocompromised patients. ParaDaseTM also has received Fast Track Designation by the U.S. FDA.

For more information, please visit www.ansunbiopharma.com or www.clinicaltrials.gov using the identifier NCT01644877.

Leave a Reply

Your email address will not be published. Required fields are marked *